Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer.

abstract：:Both the capacity of healthy human, cancer patient, and mouse plasma proteins to bind flavone acetic acid (FAA) and the qualitative differences in the plasma protein-binding site were studied. The binding capacity of plasma proteins for FAA was saturated within the therapeutic range in both species. The binding of FAA...

journal_title：Cancer chemotherapy and pharmacology

authors： Brodfuehrer J,Valeriote F,Chan K,Heilbrun L,Corbett T

更新日期：1990-01-01 00:00:00

abstract：UNLABELLED:Oxaliplatin (OPT), a third-generation platinating agent, is currently being evaluated in a phase II clinical trial in head and neck cancer patients and in a phase I clinical trial in combination with paclitaxel (TXL). PURPOSE:The aim of this study was to investigate the pharmacokinetics and biological corre...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu J,Kraut E,Bender J,Brooks R,Balcerzak S,Grever M,Stanley H,D'Ambrosio S,Gibson-D'Ambrosio R,Chan KK

更新日期：2002-05-01 00:00:00

abstract：PURPOSE:Pharmacokinetic-pharmacodynamic (PK-PD) models able to predict the action of anticancer compounds in tumor xenografts have an important impact on drug development. In case of anti-angiogenic compounds, many of the available models show difficulties in their applications, as they are based on a cell kill hypothe...

journal_title：Cancer chemotherapy and pharmacology

authors： Rocchetti M,Germani M,Del Bene F,Poggesi I,Magni P,Pesenti E,De Nicolao G

更新日期：2013-05-01 00:00:00

abstract：:Using flow cytometry and conventional spectrofluorimetry we have previously shown that chloroethylnitrosoureas (CNUs) can exhibit marked inhibition of cellular enzymes catalysing hydrolysis of fluorescein diacetate (FDA). More potent inhibition was seen for the carbamoylating CNUs, whereas alkylating agents were large...

journal_title：Cancer chemotherapy and pharmacology

authors： Dive C,Workman P,Watson JV

更新日期：1989-01-01 00:00:00

abstract：:Two studies were carried out (A and B) in order to assess the effectiveness of ifosfamide administered with mesna (IFO/M) in the treatment of small cell lung cancer. The first study (A) was a cross-over study; the second (B) was a randomized trial, and in B IFO/M was evaluated earlier in the course of the disease. IFO...

journal_title：Cancer chemotherapy and pharmacology

authors： Cantwell BM,Harris AL,Bozzino JM

更新日期：1986-01-01 00:00:00

abstract：:Sixty-seven patients with acute nonlymphoblastic leukemia (ANLL) and above the age of 60 years were randomly allocated to treatment with either prednimustine + vincristine or cycles with cytosine arabinoside and thioguanine. Of the 67 patients, 13 (19%) entered a complete remission and four a partial remission. Of 33 ...

journal_title：Cancer chemotherapy and pharmacology

authors： Lönnqvist B,Andersson B,Björkholm M,Engstedt L,Gahrton G,Hast R,Holm G,Killander A,Lantz B,Lockner D,Mellstedt H,Palmblad J,Paul C,Peterson C,Simonsson B,Stalfelt AM,Udén AM,Wadman B,Oberg G

更新日期：1982-01-01 00:00:00

abstract：:A four-fold (P less than 0.001) mean increase in iron levels was found in 18 patients (a total of 36 courses of therapy) with ovarian cancer at the end of a 5-day course of cisplatin (40 mg/m2 per day every 4-5 weeks). The kinetics of these modifications began very early (24-48 h after initiation of therapy): they rea...

journal_title：Cancer chemotherapy and pharmacology

authors： Pollera CF,Ameglio F,Reina S,Nardi M,Abbolito MR,Parracino C

更新日期：1987-01-01 00:00:00

abstract：PURPOSE:We assessed the clinical efficacy and safety of mitoxantrone hydrochloride which has been used as an anticancer drug in our hospital to treat breast cancer patients since 1993. METHODS:A group of 23 patients with breast cancer were given one course of the following regimen every 3 weeks: mitoxantrone hydrochlo...

journal_title：Cancer chemotherapy and pharmacology

authors： Katsumata K,Tomioka H,Kusama M,Aoki T,Koyanagi Y

更新日期：2003-07-01 00:00:00

abstract：PURPOSE:Sonidegib (Odomzo) selectively inhibits smoothened and suppresses the growth of hedgehog pathway-dependent tumors. A population pharmacokinetic (PK) analysis of sonidegib in healthy subjects and patients with advanced solid tumors was conducted to characterize PK, determine variability, and estimate covariate e...

journal_title：Cancer chemotherapy and pharmacology

authors： Goel V,Hurh E,Stein A,Nedelman J,Zhou J,Chiparus O,Huang PH,Gogov S,Sellami D

更新日期：2016-04-01 00:00:00

abstract：:Activation of programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T cells leads to T cell exhaustion and ultimately facilitates tumor progression. Recent success of using immune cell checkpoint inhibitors offers a great promise to treat various cancers, including bladder cancer. However, the exp...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang W,Shi L,Zhao Z,Du P,Ye X,Li D,Cai Z,Han J,Cai J

更新日期：2019-05-01 00:00:00

abstract：PURPOSE:The safety and tolerability of vandetanib (ZACTIMA; ZD6474) plus FOLFIRI was investigated in patients with advanced colorectal cancer (CRC). METHODS:Patients eligible for first- or second-line chemotherapy received once-daily oral doses of vandetanib (100 or 300 mg) plus 14-day treatment cycles of FOLFIRI. RE...

journal_title：Cancer chemotherapy and pharmacology

authors： Saunders MP,Wilson R,Peeters M,Smith R,Godwood A,Oliver S,Van Cutsem E

更新日期：2009-09-01 00:00:00

abstract：PURPOSE:Trifluorothymidine (TFT) is a fluoropyrimidine that is part of the novel combination metabolite TAS-102, in which TFT is combined with a potent thymidine phosphorylase inhibitor (TPI). TAS-102 is currently tested as an orally chemotherapeutic agent in different schedules in a phase I study. In its monophosphate...

journal_title：Cancer chemotherapy and pharmacology

authors： Temmink OH,Hoogeland MF,Fukushima M,Peters GJ

更新日期：2006-01-01 00:00:00

abstract：:Trastuzumab has deeply and radically changed the course of HER2-positive breast cancer disease. The recent development of a subcutaneous (SC) formulation of trastuzumab is an important step towards improved patients' care. SC trastuzumab at a fixed dose of 600 mg administered every 3 weeks for about 5 min provides a v...

journal_title：Cancer chemotherapy and pharmacology

authors： Launay-Vacher V

更新日期：2013-12-01 00:00:00

abstract：PURPOSE:To evaluate in vitro interactions of carboplatin, gemcitabine and paclitaxel in molecularly defined non-small-cell lung cancer lines. MATERIALS AND METHODS:Three NSCLC lines, A549 (p16-,p53 wt, Rb wt), Calu-1 (p16-, p53-, Rb+) and H596 (p16 wt, p53 mut, Rb-) were utilized. Cells were exposed to carboplatin, ge...

journal_title：Cancer chemotherapy and pharmacology

authors： Edelman MJ,Quam H,Mullins B

更新日期：2001-08-01 00:00:00

abstract：PURPOSE:Anti-epidermal growth factor receptor antibody therapy alone or in combination with irinotecan is recognized as a standard third-line treatment for KRAS wild-type unresectable metastatic colorectal cancer. However, in some cases, it is difficult to administer irinotecan after third-line treatment. Therefore, we...

journal_title：Cancer chemotherapy and pharmacology

authors： Takahashi T,Emi Y,Oki E,Kobayashi K,Tsuji A,Shimokawa M,Tanaka T,Akagi Y,Ogata Y,Baba H,Yoshida K,Natsugoe S,Maehara Y,Kyushu Study Group of Clinical Cancer (KSCC).

更新日期：2016-09-01 00:00:00

abstract：:We have recently demonstrated that continuous-infusion (CI) 5-fluorouracil (FU) eradicates human colon carcinoma cells made resistant to bolus FU in vitro. In addition, in the same experimental system, the mechanisms of resistance to pulse and CI FU were found to be different. These observations led us to test the cli...

journal_title：Cancer chemotherapy and pharmacology

authors： Mori A,Bertoglio S,Guglielmi A,Aschele C,Bolli E,Tixi L,Rosso R,Sobrero A

更新日期：1993-01-01 00:00:00

abstract：OBJECTIVE:Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase two dose (RP2D) of veliparib with pegylated liposomal doxorubicin (PLD) in brea...

journal_title：Cancer chemotherapy and pharmacology

authors： Pothuri B,Brodsky AL,Sparano JA,Blank SV,Kim M,Hershman DL,Tiersten A,Kiesel BF,Beumer JH,Liebes L,Muggia F

更新日期：2020-04-01 00:00:00

abstract：PURPOSE:Cisplatin and radiation therapy remain the current standard for treating locally advanced SCCHN. Novel treatment approaches are needed, especially in patients with human papilloma virus (HPV)-negative disease who have worse outcomes despite multimodality therapy. METHODS:Using our institutional review board ap...

journal_title：Cancer chemotherapy and pharmacology

authors： Patel K,Wen J,Magliocca K,Muller S,Liu Y,Chen ZG,Saba N,Diaz R

更新日期：2014-11-01 00:00:00

abstract：PURPOSE:Fenretinide [N-(4-hydroxyphenyl)retinamide, 4HPR], a synthetic retinoid, is a potent inducer of apoptosis in small-cell lung cancer (SCLC) cell lines that may act through the generation of reactive oxygen species, suggesting that it may enhance the activity of other cytotoxic agents. In light of 4HPR's clinical...

journal_title：Cancer chemotherapy and pharmacology

authors： Kalemkerian GP,Ou X

更新日期：1999-01-01 00:00:00

abstract：:Two patients with acute promyelocytic leukemia in first relapse received mitoxantrone 12 mg/m2/day for 5 days. Both patients received IV heparin with replacement of platelets and coagulation factors for control of disseminated intravascular coagulopathy. Both have achieved a complete remission after one course of trea...

journal_title：Cancer chemotherapy and pharmacology

authors： Mittelman A,Rieber E,Friedland ML,Arlin ZA

更新日期：1985-01-01 00:00:00

abstract：:The metabolic disposition and pharmacokinetics of TNP-470 were investigated in rhesus monkeys following intravenous administration of 5 mg/kg of [3H]-TNP-470. Rapid and extensive metabolism of parent drug to six metabolites occurred as demonstrated by the absence of unchanged drug in plasma and urine at time points as...

journal_title：Cancer chemotherapy and pharmacology

authors： Cretton-Scott E,Placidi L,McClure H,Anderson DC,Sommadossi JP

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:By a scaffold shortening strategy, a small series of retinoidal amides fenretinide (4-HPR) analogs have been synthesized from α, β-ionones and tested for their antiproliferative and differentiating activities, and antioxidant effect. METHODS:The antiproliferative activity and triggering of apoptosis of our sho...

journal_title：Cancer chemotherapy and pharmacology

authors： Anzaldi M,Viale M,Macciò C,Castagnola P,Oliveri V,Rosano C,Balbi A

更新日期：2017-04-01 00:00:00

abstract：BACKGROUND:Docetaxel has marked inter-patient PK variability, and metabolic phenotypic probes may enable individualised dosing. This is the first report directly comparing the erythromycin breath test (EBT) (a CYP3A4 probe) with the antipyrine clearance test (ACT), (a general CYP-P450/predominant CYP3A4 probe) for the ...

journal_title：Cancer chemotherapy and pharmacology

authors： Michael M,Cullinane C,Hatzimihalis A,O'Kane C,Milner A,Booth R,Schlicht S,Clarke SJ,Francis P

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Camptothecin (CPT) is an anticancer agent that kills cells by converting DNA topoisomerase I into a DNA-damaging agent. Although CPT and its derivatives are now being used to treat tumors in a variety of clinical protocols, the low water solubility of the drug and its unique pharmacodynamics and reactivity i...

journal_title：Cancer chemotherapy and pharmacology

authors： Minko T,Paranjpe PV,Qiu B,Lalloo A,Won R,Stein S,Sinko PJ

更新日期：2002-08-01 00:00:00

abstract：:The pharmacokinetic parameters of the alkylating agent melphalan were determined in 15 children and 11 adults with advanced malignant solid tumors. High IV bolus doses of 140 mg/m2 were given under standard hyperhydration conditions and followed by autologous bone marrow grafting. In all cases the time-concentration c...

journal_title：Cancer chemotherapy and pharmacology

authors： Ardiet C,Tranchand B,Biron P,Rebattu P,Philip T

更新日期：1986-01-01 00:00:00

abstract：PURPOSE:Chemotherapy dosing in neonates represents a major clinical challenge because of a lack of clinical pharmacology information in this patient population. In this study, we investigate the use of cisplatin dose adaptation based on therapeutic drug monitoring in a 2-week-old neonate with localized hepatoblastoma. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Thomas F,Veal GJ,El Balkhi S,Lafont T,Picard N,Brugières L,Chatelut E,Piguet C

更新日期：2018-08-01 00:00:00

abstract：:We used a microdialysis technique to determine tissue methotrexate (MTX) levels during steady state in a rodent model. Two different approaches were employed to measure the actual extracellular MTX concentrations in muscle, liver, and kidney tissues of anesthetized Wistar rats. With the reduced-perfusion-rate techniqu...

journal_title：Cancer chemotherapy and pharmacology

authors： Ekstrøm PO,Andersen A,Warren DJ,Giercksky KE,Slørdal L

更新日期：1996-01-01 00:00:00

abstract：:BS compounds, a series of new dihydropyridines, successfully overcame multidrug resistance in P388/ADR cells in vitro. These agents synergistically potentiated the cytotoxicity of Adriamycin to P388/ADR cells at a concentration of 1-2 microM, whereas they showed hardly any synergistic effect in the parental cell line ...

journal_title：Cancer chemotherapy and pharmacology

authors： Yoshinari T,Iwasawa Y,Miura K,Takahashi IS,Fukuroda T,Suzuki K,Okura A

更新日期：1989-01-01 00:00:00

abstract：BACKGROUND:STAT3 overexpression has been detected in several cancers including head and neck squamous cell carcinoma (HNSCC). Previous studies using intratumoral administration of a STAT3 decoy oligonucleotide that abrogates STAT3-mediated gene transcription in preclinical cancer models have demonstrated antitumor effi...

journal_title：Cancer chemotherapy and pharmacology

authors： Sen M,Tosca PJ,Zwayer C,Ryan MJ,Johnson JD,Knostman KA,Giclas PC,Peggins JO,Tomaszewski JE,McMurray TP,Li C,Leibowitz MS,Ferris RL,Gooding WE,Thomas SM,Johnson DE,Grandis JR

更新日期：2009-05-01 00:00:00

abstract：:Fifty-four patients whose disease had been staged as extensive small cell carcinoma of the bronchus were randomised to receive either CAV1 (cyclophosphamide 600 mg m-2 i.v., adriamycin 50 mg m-2 i.v., given on day 1, and etoposide 500 mg m-2 p.o. given on day 3) or CAV5 (cyclophosphamide and adriamycin given as for CA...

journal_title：Cancer chemotherapy and pharmacology

authors： Mead GM,Thompson J,Sweetenham JW,Buchanan RB,Whitehouse JM,Williams CJ

更新日期：1987-01-01 00:00:00